CN117295497A - 用于治疗脑梗塞的药物组合物 - Google Patents

用于治疗脑梗塞的药物组合物 Download PDF

Info

Publication number
CN117295497A
CN117295497A CN202280033982.7A CN202280033982A CN117295497A CN 117295497 A CN117295497 A CN 117295497A CN 202280033982 A CN202280033982 A CN 202280033982A CN 117295497 A CN117295497 A CN 117295497A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cerebral infarction
administered
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033982.7A
Other languages
English (en)
Chinese (zh)
Inventor
西村直子
莲见惠司
本田一男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN117295497A publication Critical patent/CN117295497A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202280033982.7A 2021-05-10 2022-05-10 用于治疗脑梗塞的药物组合物 Pending CN117295497A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079820 2021-05-10
JP2021-079820 2021-05-10
PCT/US2022/028488 WO2022240810A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Publications (1)

Publication Number Publication Date
CN117295497A true CN117295497A (zh) 2023-12-26

Family

ID=82214306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033982.7A Pending CN117295497A (zh) 2021-05-10 2022-05-10 用于治疗脑梗塞的药物组合物

Country Status (9)

Country Link
US (1) US20240238248A1 (enExample)
EP (1) EP4337193A1 (enExample)
JP (1) JP2024525998A (enExample)
KR (1) KR20240005749A (enExample)
CN (1) CN117295497A (enExample)
AU (1) AU2022275263A1 (enExample)
BR (1) BR112023023534A2 (enExample)
CA (1) CA3216137A1 (enExample)
WO (1) WO2022240810A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
CN102470124A (zh) * 2009-07-06 2012-05-23 国立大学法人东京农工大学 细胞保护剂
US20200140450A1 (en) * 2018-11-02 2020-05-07 Showa University Chemical method of producing smtp groups or smtp-7 and intermediates used in the method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
CN121064221A (zh) * 2021-02-10 2025-12-05 福建盛迪医药有限公司 一种smtp-7衍生物及其用途
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
CN102470124A (zh) * 2009-07-06 2012-05-23 国立大学法人东京农工大学 细胞保护剂
US20200140450A1 (en) * 2018-11-02 2020-05-07 Showa University Chemical method of producing smtp groups or smtp-7 and intermediates used in the method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIRONOBU SAWADA; NAOKO NISHIMURA; ERIKO SUZUKI; JIE ZHUANG; KEIKO HASEGAWA; HIROYUKI TAKAMATSU; KAZUO HONDA; KEIJI HASUMI: "SMTP-7, a Novel Small-Molecule Thrombolytic for Ischemic Stroke: A Study in Rodents and Primates", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 34, no. 2, 14 February 2014 (2014-02-14), pages 235 - 241 *
MATSUMOTO NAOKI; SUZUKI ERIKO; ISHIKAWA MAKOTO; SHIRAFUJI TAKUMI; HASUMI KEIJI: "Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7", THE JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 289, no. 52, 31 December 2014 (2014-12-31), pages 35826 - 38 *
SUZUKI ERIKO; NISHIMURA NAOKO; YOSHIKAWA TETSUYA; KUNIKIYO YUDAI; HASEGAWA KEIKO; HASUMI KEIJI: "Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys", PHARMACOLOGY RESEARCH & PERSPECTIVES, vol. 6, no. 6, 31 December 2018 (2018-12-31), pages 00448 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Also Published As

Publication number Publication date
AU2022275263A1 (en) 2023-11-09
EP4337193A1 (en) 2024-03-20
BR112023023534A2 (pt) 2024-01-30
JP2024525998A (ja) 2024-07-16
US20240238248A1 (en) 2024-07-18
KR20240005749A (ko) 2024-01-12
CA3216137A1 (en) 2022-11-17
WO2022240810A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
JP7042531B2 (ja) デオキシコール酸を含む医薬組成物
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
JP2019526542A (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
CN108472275A (zh) 治疗缺血性中风的组合物及方法
CN110167538B (zh) 用于治疗心血管疾病的方法
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
US20200147050A1 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
DE60301862T2 (de) Kombinationsbehandlung bei akutem myokardinfarkt
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
US20070123567A1 (en) Prophylactic pretreatment with antioxidants
Kurosawa et al. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and Baloxavir Marboxil in a patient on implantable ventricular assist device
JP2006510613A (ja) ３，７−ジアザビシクロ［３．３．１］ノナン化合物を含有する液体医薬組成物および抗不整脈事象に関する治療法
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
JP4925406B2 (ja) 糖尿病性腎症の予防及び／又は治療剤
WO2025229186A1 (en) Composition for use in reducing the risk of recurrent acute urinary retention
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
JPH0826994A (ja) 脳血管攣縮治療剤
NZ543221A (en) Anti-rotation foot for strainer post
HK1216857A1 (en) Nitroxyl donors with improved therapeutic index

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240510

Address after: Room 1902, 19th floor, Lee Garden Phase I, 33 Hysan Road, Causeway Bay, Hong Kong, China

Applicant after: Jixing Pharmaceutical Hong Kong Ltd.

Country or region after: Hong-Kong

Address before: Massachusetts, USA

Applicant before: Bojian Massachusetts Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105798

Country of ref document: HK